IL163814A0 - Virus-like particles of human papillomavirus - Google Patents

Virus-like particles of human papillomavirus

Info

Publication number
IL163814A0
IL163814A0 IL16381403A IL16381403A IL163814A0 IL 163814 A0 IL163814 A0 IL 163814A0 IL 16381403 A IL16381403 A IL 16381403A IL 16381403 A IL16381403 A IL 16381403A IL 163814 A0 IL163814 A0 IL 163814A0
Authority
IL
Israel
Prior art keywords
virus
particles
human papillomavirus
papillomavirus
human
Prior art date
Application number
IL16381403A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IL163814A0 publication Critical patent/IL163814A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
IL16381403A 2002-03-18 2003-03-17 Virus-like particles of human papillomavirus IL163814A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0206360.0A GB0206360D0 (en) 2002-03-18 2002-03-18 Viral antigens
PCT/EP2003/002826 WO2003077942A2 (en) 2002-03-18 2003-03-17 Virus-like particles of human papillomavirus

Publications (1)

Publication Number Publication Date
IL163814A0 true IL163814A0 (en) 2005-12-18

Family

ID=9933201

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16381403A IL163814A0 (en) 2002-03-18 2003-03-17 Virus-like particles of human papillomavirus
IL163814A IL163814A (en) 2002-03-18 2004-08-30 Virus-like particles of papilloma virus of human origin

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL163814A IL163814A (en) 2002-03-18 2004-08-30 Virus-like particles of papilloma virus of human origin

Country Status (25)

Country Link
US (3) US7217419B2 (ja)
EP (2) EP1492562A2 (ja)
JP (2) JP2005524674A (ja)
KR (2) KR20050002868A (ja)
CN (1) CN100528226C (ja)
AP (1) AP1872A (ja)
AR (1) AR039005A1 (ja)
AU (1) AU2003218787B2 (ja)
BR (1) BR0308444A (ja)
CA (1) CA2479304C (ja)
EA (1) EA011477B1 (ja)
EC (1) ECSP045300A (ja)
GB (1) GB0206360D0 (ja)
IL (2) IL163814A0 (ja)
IS (1) IS7426A (ja)
MX (1) MXPA04009060A (ja)
MY (1) MY139031A (ja)
NO (1) NO20044326L (ja)
NZ (1) NZ535085A (ja)
OA (1) OA12787A (ja)
PL (1) PL212981B1 (ja)
TW (1) TW200400046A (ja)
UA (1) UA85536C2 (ja)
WO (1) WO2003077942A2 (ja)
ZA (1) ZA200407029B (ja)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US8956621B2 (en) * 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
DE122007000087I1 (de) * 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7276243B2 (en) * 2003-03-24 2007-10-02 Merck & Co., Inc. Optimized expression of HPV31 L1 in yeast
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
KR20070029254A (ko) * 2004-06-16 2007-03-13 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US8399610B2 (en) * 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
BRPI0607097B8 (pt) 2005-02-01 2021-05-25 The Gorvernment Of The United States Of America Repres By The Secretary Depart Of Health And Human S uso de um peptídeo imunogênico para a fabricação de um medicamento para o tratamento, prevenção ou redução de infecção por papilomavírus
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006114273A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
AU2006239422A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
CN1328287C (zh) * 2005-12-29 2007-07-25 西安交通大学 Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途
US8101342B2 (en) 2006-08-28 2012-01-24 Sungkyunkwan University Foundation For Corporate Collaboration DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein
SI2601970T1 (sl) 2006-09-29 2017-04-26 Takeda Vaccines, Inc. Formulacije cepiva proti norovirusu
US20100272753A1 (en) * 2006-10-26 2010-10-28 The Johns Hopkins University Recombinant Adenovirus Vaccines
WO2008115631A2 (en) * 2007-02-08 2008-09-25 University Of Louisville Research Foundation, Inc. Plant-produced compositions for treating papillomavirus infection and related methods
AU2008226974B2 (en) * 2007-03-09 2013-08-15 Merck Sharp & Dohme Llc Papillomavirus vaccine compositions
DK2154147T3 (en) 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
BRPI0815818A2 (pt) * 2007-04-29 2016-08-02 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 truncada do papiloma vírus humano tipo 18
WO2008145021A1 (en) * 2007-05-29 2008-12-04 Xiamen University A truncated l1 protein of human papillomavirus 6
US8088392B2 (en) * 2007-06-18 2012-01-03 Yunxu Cao Capsid proteins and uses therefore
WO2008154867A1 (en) * 2007-06-18 2008-12-24 Shanghai Zerun-Ankegens Biopharmaceutical Co., Ltd Material with immunogenicity
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
US8100843B2 (en) * 2009-03-24 2012-01-24 GM Global Technology Operations LLC Shape memory polymer medical cast
MA33440B1 (fr) * 2009-06-25 2012-07-03 Glaxosmithkline Biolog Sa Nouvelles compositions
CN102178944A (zh) * 2010-09-17 2011-09-14 大连雅立峰生物制药有限公司 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用
AU2012282658B2 (en) 2011-07-11 2014-11-27 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
CN102552897B (zh) * 2012-01-18 2013-10-30 广东华南联合疫苗开发院有限公司 一种宫颈癌预防性vlp疫苗
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CN104211782B (zh) * 2013-06-04 2017-11-17 厦门大学 截短的人乳头瘤病毒45型l1蛋白
MY195018A (en) * 2014-10-24 2023-01-03 Hpvvax Llc Cancer and skin lesion treatment
US10799574B2 (en) * 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
EP3419661A4 (en) * 2016-02-27 2019-10-23 Hpvvax, Llc METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN INJURY USING A VACCINE

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DE122007000019I1 (de) 1991-07-19 2007-07-26 Univ Queensland Impfstoffen gegen Papillomavirus
DE122007000095I1 (de) 1992-06-25 2008-03-27 Papillomavirus vakzine
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
ATE296111T1 (de) 1993-03-09 2005-06-15 Univ Rochester Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE328068T1 (de) 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
WO1996011272A2 (de) * 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
JP3693449B2 (ja) 1996-04-05 2005-09-07 三菱製紙株式会社 抗菌防黴剤およびそれを含有する繊維状物質
KR20010006169A (ko) 1997-04-08 2001-01-26 폴락 돈나 엘. 안정화된 사람 파필로마바이러스 제형물
ES2268787T3 (es) 1997-09-05 2007-03-16 Medimmune, Inc. Metodo in vitro de desmontaje/embalaje de particulas similares a virus (vlp) de papilomavirus.
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
BR9908599A (pt) 1998-03-09 2000-11-14 Smithkline Beecham Biolog Composições combinadas de vacina
GB9806666D0 (en) 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
DE69924262T3 (de) 1998-08-14 2009-07-23 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen
CA2339034C (en) * 1998-08-14 2010-10-12 Merck & Co., Inc. Process for purifying human papillomavirus virus-like particles
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
EP1150712B1 (en) 1999-02-05 2008-11-05 Merck & Co., Inc. Human papilloma virus vaccine formulations
US6245568B1 (en) * 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
KR100808348B1 (ko) 2000-01-31 2008-02-27 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｉｖ에 대한 예방 또는 치료용 면역화를 위한 백신
US6908613B2 (en) 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
AU2001275438A1 (en) * 2000-07-06 2002-01-21 Georgetown University Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
AU2003213060A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
OA13147A (en) 2002-12-20 2006-12-13 Glaxosmithkline Biolog Sa HPV-16 and -18 L1 VLP vaccine.
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Also Published As

Publication number Publication date
NZ535085A (en) 2006-08-31
AU2003218787B2 (en) 2006-04-06
CA2479304C (en) 2013-10-08
PL212981B1 (pl) 2012-12-31
EP2044953A1 (en) 2009-04-08
US20070224218A1 (en) 2007-09-27
IL163814A (en) 2009-07-20
JP2005524674A (ja) 2005-08-18
US20050175632A1 (en) 2005-08-11
KR20050002868A (ko) 2005-01-10
CN1642571A (zh) 2005-07-20
AP1872A (en) 2008-08-04
AP2004003136A0 (en) 2004-09-30
US7217419B2 (en) 2007-05-15
WO2003077942A3 (en) 2003-12-24
US7815915B2 (en) 2010-10-19
JP2010090158A (ja) 2010-04-22
CN100528226C (zh) 2009-08-19
WO2003077942A2 (en) 2003-09-25
ECSP045300A (es) 2005-01-03
IS7426A (is) 2004-09-15
US20080279890A1 (en) 2008-11-13
BR0308444A (pt) 2005-01-18
GB0206360D0 (en) 2002-05-01
EA200401064A1 (ru) 2005-04-28
TW200400046A (en) 2004-01-01
PL372937A1 (en) 2005-08-08
AU2003218787A1 (en) 2003-09-29
NO20044326D0 (no) 2004-10-12
OA12787A (en) 2006-07-10
NO20044326L (no) 2004-10-14
AR039005A1 (es) 2005-02-02
KR20110009249A (ko) 2011-01-27
MXPA04009060A (es) 2005-01-25
EA011477B1 (ru) 2009-04-28
ZA200407029B (en) 2005-11-30
UA85536C2 (en) 2009-02-10
US7416846B2 (en) 2008-08-26
CA2479304A1 (en) 2003-09-25
EP1492562A2 (en) 2005-01-05
MY139031A (en) 2009-08-28

Similar Documents

Publication Publication Date Title
IL163814A0 (en) Virus-like particles of human papillomavirus
ZA200502618B (en) Human papillomavirus polypeptides and immunogenic compositions
HK1082524A1 (zh) α-病毒粒子及製造方法
AU2003223207A8 (en) Scds as modifiers of the p53 pathway and methods of use
AU2003225705A1 (en) Cytidine analogs and methods of use
EP1828414A4 (en) DETECTION OF HUMAN PAPILLOMA VIRUS
HK1084949A1 (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
GB0200744D0 (en) Preparation of nanoparticles
TWI349557B (en) Use of hpv 16 and hpv 18 vlps for vaccine preparation
AU2003275056A1 (en) Novel lapacho compounds and methods of use thereof
AU2003290012A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
GB0324147D0 (en) Functionilisation of particles
EP1534512A4 (en) COATED PARTICLES, MANUFACTURING AND USE METHOD
GB2387096B (en) Tomography of curved surfaces
GB0200258D0 (en) Detection of human papillomavirus
EP1617810A4 (en) PROCESS FOR THE PREPARATION AND USE OF 1ALPHA, 24 (S) -DIHYDROXYVITAMINE D2
GB0201382D0 (en) Virus-like particles
AU2003300772A1 (en) Preventive and therapeutic aids vaccines
EP1697349A4 (en) DOXEPINE ANALOGUES AND METHODS OF USE
GB0207242D0 (en) Universal detection of human papillomavirus mRNA
AU2003239773A1 (en) Preparation of vaccines
AU2003228816A8 (en) Production of papillomavirus vaccines in plants
AU2003243215A1 (en) Treatment for human papillomavirus
GB0215988D0 (en) Detection of human papillomavirus mRNA
HK1087619A1 (en) Oral suspension of tegaserod